Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of BI 456906 once weekly versus placebo in adults with obesity or overweight
NL-OMON51000Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- May 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of survodutide in obesity and Overweight (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage change in body weight from baseline to week 46. Started May 2021; status: active, not recruiting.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NL-OMON51000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51000.